Clinical trial
Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating…
NCT00496704 · Yonsei University, Other · Unknown status
Key facts
| NCT number | NCT00496704 |
|---|---|
| Title | Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan |
| Official title | A Phase I/II Study to Determine the Safety and Efficacy of Second-Line Treatment With XELOX Plus Gemcitabine in Irinotecan Pre-Treated Advanced Colorectal Cancer Patients |
| Lead sponsor | Yonsei University, Other |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, gemcitabine hydrochloride, oxaliplatin |
| Enrollment | 56 |
| Start date | Jan 1, 2007 |
| Primary completion | Aug 1, 2009 |
| First posted | Jul 4, 2007 |
| Last update posted | Aug 21, 2009 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: